Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
18%
Ph phase_1
1
9%
Ph phase_3
5
45%
Ph phase_2
3
27%

Phase Distribution

1

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
5(45.5%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(11)

Detailed Status

Completed11

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (9.1%)
Phase 23 (27.3%)
Phase 35 (45.5%)
N/A2 (18.2%)

Trials by Status

completed11100%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

NCT02345044
completedphase_2

A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment

NCT02448628
completedphase_3

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

NCT02722265
completedphase_1

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
completedphase_3

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

NCT02807974
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02345044Phase 2

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

Completed
NCT02448628Phase 2

A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment

Completed
NCT02722265Phase 3

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Completed
NCT04019652Phase 1

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

Completed
NCT02807974Phase 3

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Completed
NCT02345057Phase 2

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria

Completed
NCT02848170Not Applicable

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Completed
NCT02807987Phase 3

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Completed
NCT02890173Phase 3

Study of CS-3150 in Patients With Essential Hypertension

Completed
NCT02885662Not Applicable

Study of CS-3150 in Patients With Primary Aldosteronism

Completed
NCT02808026Phase 3

Study of CS-3150 in Patients With Severe Hypertension

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11